Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro.

Amrein L, Hernandez TA, Ferrario C, Johnston J, Gibson SB, Panasci L, Aloyz R.

Br J Haematol. 2008 Dec;143(5):698-706. doi: 10.1111/j.1365-2141.2008.07418.x .

PMID:
19062342
2.

Quantification of change in phosphorylation of BCR-ABL kinase and its substrates in response to Imatinib treatment in human chronic myelogenous leukemia cells.

Liang X, Hajivandi M, Veach D, Wisniewski D, Clarkson B, Resh MD, Pope RM.

Proteomics. 2006 Aug;6(16):4554-64.

PMID:
16858728
3.

Role of Dok-1 and Dok-2 in leukemia suppression.

Niki M, Di Cristofano A, Zhao M, Honda H, Hirai H, Van Aelst L, Cordon-Cardo C, Pandolfi PP.

J Exp Med. 2004 Dec 20;200(12):1689-95.

4.

Role of Dok-1 and Dok-2 in myeloid homeostasis and suppression of leukemia.

Yasuda T, Shirakata M, Iwama A, Ishii A, Ebihara Y, Osawa M, Honda K, Shinohara H, Sudo K, Tsuji K, Nakauchi H, Iwakura Y, Hirai H, Oda H, Yamamoto T, Yamanashi Y.

J Exp Med. 2004 Dec 20;200(12):1681-7.

5.

Molecular cloning and characterization of p56dok-2 defines a new family of RasGAP-binding proteins.

Di Cristofano A, Carpino N, Dunant N, Friedland G, Kobayashi R, Strife A, Wisniewski D, Clarkson B, Pandolfi PP, Resh MD.

J Biol Chem. 1998 Feb 27;273(9):4827-30.

Supplemental Content

Loading ...
Support Center